Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study-Reference-Cited by-同舟云学术

Efficacy and safety of nivolumab in Japanese patients with previously untreated advanced melanoma: A phase II study

Published:2017-06 Issue:6 Volume:108 Page:1223-1230
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Yamazaki Naoya¹^ORCID,Kiyohara Yoshio²,Uhara Hisashi³,Uehara Jiro⁴,Fujimoto Manabu⁵,Takenouchi Tatsuya⁶,Otsuka Masaki⁷,Uchi Hiroshi⁸,Ihn Hironobu⁹,Minami Hironobu¹⁰

Affiliation:

1. Department of Dermatologic Oncology; National Cancer Center Hospital; Tokyo Japan

2. Dermatology Division; Shizuoka Cancer Center Hospital; Shizuoka Japan

3. Department of Dermatology; Shinshu University School of Medicine; Nagano Japan

4. Department of Dermatology; Asahikawa Medical University; Hokkaido Japan

5. Department of Dermatology; University of Tsukuba Hospital; Ibaraki Japan

6. Department of Dermatology; Niigata Cancer Center Hospital; Niigata Japan

7. Department of Dermatology; Okayama University Graduate School of Medicine; Dentistry and Pharmaceutical Sciences; Okayama Japan

8. Department of Dermatology; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

9. Department of Dermatology and Plastic Surgery; Faculty of Life Sciences; Kumamoto University; Kumamoto Japan

10. Department Medical Oncology/Hematology; Kobe University Graduate School of Medicine; Hyogo Japan

Funder

Ono Pharmaceutical Co. Ltd

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cas.13241/fullpdf

Reference35 articles.

1. Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study;Avril;J Clin Oncol,2004

2. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma;Middleton;J Clin Oncol,2000

3. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma;Balch;J Clin Oncol,2001

4. Final version of 2009 AJCC melanoma staging and classification;Balch;J Clin Oncol,2009

5. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation;Freeman;J Exp Med,2000

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cutaneous Adverse Reactions and Survival Outcomes of Advanced Melanoma Treated with Immune Checkpoint Inhibitors in an Academic Medical Centre in Singapore;Diagnostics;2024-07-25

2. Efficacy and Safety of Salvage-line Nivolumab Monotherapy for Advanced Esophageal Squamous Cell Carcinoma: Comparison of 240 mg Versus 480 mg Doses;Journal of Gastrointestinal Cancer;2024-07-15

3. Efficacy and safety of salvage-line nivolumab monotherapy for advanced esophageal squamous cell carcinoma: Comparison of 240 mg versus 480 mg doses;2024-05-02

4. Long‐term survival with systemic therapy in the last decade: Can melanoma be cured?;The Journal of Dermatology;2024-02-15

5. Optimal strategy in managing advanced melanoma;The Journal of Dermatology;2023-12-12